Company cbdMD, Inc.

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:00:00 2026-06-08 pm EDT			5-day change	1st Jan Change
0.7200 ^USD	-0.48%		-8.63%	-46.67%

May. 14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
May. 14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE

Business description: cbdMD, Inc.

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Number of employees: 42

Sales by Activity: cbdMD, Inc.

Fiscal Period: September	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Pharmaceuticals	-	-	-	-	19.19M

See all business segments

Geographical breakdown of sales: cbdMD, Inc.

Fiscal Period: September	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	44.48M	35.4M	24.16M	19.48M	19.19M

See all geographic segments

Executive Committee: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	2023-02-28
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	2018-12-31
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-
Wade Brown SAM	Sales & Marketing	-	2025-02-28
Joe Baghadjian SAM	Sales & Marketing	-	2023-12-31

See CBDMD, INC. governance

Composition of the Board of Directors: cbdMD, Inc.

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	2017-02-28
William Raines BRD	Director/Board Member	66	2019-04-18
Scott Stephen CHM	Chairman	60	2022-06-02
T. Kennedy BRD	Director/Board Member	47	2024-12-17
Sibyl Swift BRD	Director/Board Member	45	-
Jeffrey Porter BRD	Director/Board Member	66	2025-04-09
Kevin Roe BRD	Director/Board Member	53	2025-04-09

Composition of the Board of Directors

Shareholders: cbdMD, Inc.

Name	Stocks	%	Valuation
Jeffrey Porter 5.493 %	576,674	5.493 %	456 726 $
Crc Investment Fund LP 4.155 %	436,150	4.155 %	345 431 $
Worth Venture Partners LLC 1.76 %	184,796	1.76 %	146 358 $
UBS Financial Services, Inc. 1.568 %	164,643	1.568 %	130 397 $
CSS LLC 1.311 %	137,621	1.311 %	108 996 $

List of CBDMD, INC. shareholders

Company details: cbdMD, Inc.

cbdMD, Inc.

2101 Westinghouse Boulevard

28273, Charlotte

http://www.cbdmd.com

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	-0.48%	-8.63%	-24.65%	-94.83%	7.56M
ELI LILLY AND COMPANY	+1.57%	+6.19%	+49.26%	+157.85%	1,025B
JOHNSON & JOHNSON	-0.26%	+3.87%	+49.75%	+44.86%	559B
ABBVIE INC.	-1.83%	+4.76%	+17.51%	+62.07%	394B
ROCHE HOLDING AG	-2.20%	+3.06%	+21.96%	+15.20%	324B
MERCK & CO., INC.	-1.05%	+3.78%	+51.35%	+8.34%	295B
ASTRAZENECA PLC	-1.84%	+2.69%	+25.97%	+15.86%	286B
NOVARTIS AG	-0.31%	+3.40%	+19.75%	+29.58%	270B
NOVO NORDISK A/S	-1.72%	-3.80%	-48.61%	-51.06%	186B
AMGEN INC.	-1.10%	+5.04%	+19.08%	+56.61%	187B
Average	-0.59%	+1.92%	+18.14%	+24.45%	352.62B
Weighted average by Cap.	-0.37%	+4.02%	+32.54%	+65.87%